Hudson Bay Capital Management
EWTX icon

Hudson Bay Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Hudson Bay Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$1.1M – 1463
2025
Q1 		$1.1M Buy
+50,000
New +$1.31M ﹤0.01% 908

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hudson Bay Capital Management's EWTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 12,930 shares — an estimated $407K sold.

Hudson Bay Capital Management first reported a position in EWTX in Q4 2023 and held it in 3 quarters. The position peaked at $13M in Q4 2023. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 12,930 Edgewise Therapeutics shares in Q2 2026, an estimated $407K.
  • Hudson Bay Capital Management first reported a position in Edgewise Therapeutics in Q4 2023 and held it in 3 quarters.
  • Hudson Bay Capital Management's Edgewise Therapeutics position peaked at $13M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.